Klaus Mendla

903 total citations
20 papers, 750 citations indexed

About

Klaus Mendla is a scholar working on Molecular Biology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Klaus Mendla has authored 20 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Physiology and 8 papers in Cellular and Molecular Neuroscience. Recurrent topics in Klaus Mendla's work include Receptor Mechanisms and Signaling (10 papers), Alzheimer's disease research and treatments (6 papers) and Neuroscience and Neuropharmacology Research (6 papers). Klaus Mendla is often cited by papers focused on Receptor Mechanisms and Signaling (10 papers), Alzheimer's disease research and treatments (6 papers) and Neuroscience and Neuropharmacology Research (6 papers). Klaus Mendla collaborates with scholars based in Germany, United States and Belgium. Klaus Mendla's co-authors include Anja Capell, Brigitte Pesold, Christian Haass, Dennis J. Selkoe, Martin Citron, Helmut Romig, Helmut A. Ensinger, Michael Cantz, Harald Steiner and Peter M. Kloetzel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemical Journal.

In The Last Decade

Klaus Mendla

20 papers receiving 712 citations

Peers

Countries citing papers authored by Klaus Mendla

Since Specialization

Citations

This map shows the geographic impact of Klaus Mendla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Mendla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Mendla more than expected).

Fields of papers citing papers by Klaus Mendla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Mendla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Mendla. The network helps show where Klaus Mendla may publish in the future.

Co-authorship network of co-authors of Klaus Mendla

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Mendla. A scholar is included among the top collaborators of Klaus Mendla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Mendla. Klaus Mendla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Talsaclidine (WAL 2014 FU), a muscarinic M₁ receptor agonist for the treatment of Alzheimer's disease 2002 ·Drug Development Research ·M. Wienrich, Angelo Ceci, Helmut A. Ensinger, Wolfram Gaida, Klaus Mendla, Takeshi Osugi, (unknown), Thomas Weiser	13
2	Protein kinase Cα and β1 isoforms are regulators of α‐secretory proteolytic processing of amyloid precursor protein in vivo 2001 ·European Journal of Neuroscience ·Steffen Roßner, Klaus Mendla, Reinhard Schliebs, Volker Bigl	29
3	Constitutive overactivation of protein kinase C in guinea pig brain increases α‐secretory APP processing without decreasing β‐amyloid generation 2000 ·European Journal of Neuroscience ·(unknown), Mike Beck, (unknown), Klaus Mendla, Reinhard Schliebs, Volker Bigl	37
4	Expression of Alzheimer’s Disease-associated Presenilin-1 Is Controlled by Proteolytic Degradation and Complex Formation 1998 ·Journal of Biological Chemistry ·Harald Steiner, Anja Capell, Brigitte Pesold, Martin Citron, Peter M. Kloetzel, Dennis J. Selkoe, Helmut Romig, Klaus Mendla, Christian Haass	165
5	Muscarinic m1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain 1997 ·Life Sciences ·(unknown), Klaus Mendla, Steven Farber, Roger M. Nitsch	65
6	Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease 1997 ·Neuroscience Letters ·Sidonie Golombowski, F. Müller‐Spahn, Helmut Romig, Klaus Mendla, Christoph Höck	33
7	Wal 2014 fu: Affinity for muscarinic receptors from rat tissues and for human muscarinic receptors expressed in cho cells and functional efficacy in vitro 1997 ·Life Sciences ·Helmut A. Ensinger, Klaus Mendla, G. Speck, Rudolf Hammer	1
8	Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C 1997 ·Proceedings of the National Academy of Sciences ·Jochen Walter, Jürgen Grünberg, Anja Capell, Brigitte Pesold, Alice Schindzielorz, Martin Citron, Klaus Mendla, Peter St George‐Hyslop, Gerd Multhaup, Dennis J. Selkoe, Christian Haass	94
9	WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease 1997 ·Drug Development Research ·Helmut A. Ensinger, (unknown), F.W. Birke, Klaus Mendla, Joachim Mierau, G. Speck, (unknown)	12
10	Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders 1994 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown), A. Brambilla, (unknown), Wolfram Gaida, Klaus Mendla, Eugenia Monferini, Nikolaos Pitsikas, G.B. Schiavi, A. Sagrada	6
11	Therapeutic potential of CNS-active M2 antagonists: Novel structures and pharmacology 1993 ·Life Sciences ·H. N. Doods, Rémi Quirion, Gerhard Mihm, W. Engel, K Rudolf, Michael Entzeroth, G.B. Schiavi, H. Ladinsky, (unknown), Helmut A. Ensinger, Klaus Mendla, Wolfgang Eberlein	58
12	WAL 2014 - A muscarinic agonist with preferential neuron-stimulating properties 1993 ·Life Sciences ·Helmut A. Ensinger, H. N. Doods, (unknown), (unknown), G. Lambrecht, Klaus Mendla, (unknown), E. Mutschler, A. Sagrada, Guillaume Walther, Rudolf Hammer	35
13	Distribution of the muscarinic receptor subtypes in rat olfactory bulb as determined with three selective second generation antagonists DAU 6202, AQ-RA 741 and DAG 5600 1993 ·Life Sciences ·G.B. Schiavi, Lucilla D. Monti, Klaus Mendla, (unknown), (unknown), Wolfgang Eberlein, Marco Turconi, H. Ladinsky	2
14	Human M1 receptor-transfected RBL cells: A novel test system for the characterization of muscarinic agonists 1993 ·Life Sciences ·Klaus Mendla, S V Jones, D. Arndts, Helmut A. Ensinger, Mark R. Brann	1
15	Cloning and functional characterization of a human Al adenosine receptor 1992 ·Biochemical and Biophysical Research Communications ·Frédérick Libert, Jacqueline Van Sande, Anne Lefort, A.P. Czernilofsky, Jacques E. Dumont, Gilbert Vassart, Helmut A. Ensinger, Klaus Mendla	100
16	Defective lysosomal release of glycoprotein-derived sialic acid in fibroblasts from patients with sialic acid storage disease 1988 ·Biochemical Journal ·Klaus Mendla, (unknown), (unknown), (unknown), Michael Cantz	24
17	Prenatal diagnosis and confirmation of infantile sialic acid storage disease 1986 ·Prenatal Diagnosis ·Eszter P. Vamos, Jacques Libert, (unknown), Eric Jauniaux, J. Hustin, Paul Wilkin, (unknown), Klaus Mendla, Michael Cantz, G Strecker	22
18	N-Acetylneuraminic acid storage disease 1985 ·Human Genetics ·(unknown), Michael Cantz, Klaus Mendla, Wolfgang Baumann, H. Friebolin, J. Gehler, Jürgen W. Spranger	26
19	Specificity studies on the oligosaccharide neuraminidase of human fibroblasts 1984 ·Biochemical Journal ·Klaus Mendla, Michael Cantz	20
20	PARTIAL DEFICIENCY OF GLYCOPROTEIN NEURAMINIDASE IN SOME PATIENTS WITH MORQUIO DISEASE TYPE A 1984 ·Pediatric Research ·Josef Glössl, Hans Kresse, Klaus Mendla, Michael Cantz, W Rosenkranz	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact